MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
PR Newswire
LOS ANGELES, Aug. 3, 2026
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofMapLight Therapeutics, Inc. ("MapLight" or "the Company") (NASDAQ: MPLT) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On July 27, 2026, MapLight shares fell more than 50% in premarket trading after its Phase 2 trial reported mixed results for its schizophrenia drug candidate. According to the Company, "The 330/6 mg once-daily dose, which results in lower daily exposure than BID dosing, demonstrated numerical improvement over placebo, but did not achieve statistical significance on the primary endpoint, MapLight Therapeutics (MPLT) noted." Based on this news, shares of MapLight opened down 65% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.com
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
SOURCE Schall, Brown & Schwartz LLP
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
September Stock Market Outlook: How to Position Your Portfolio During a Risky Stage
If You’re Worried About Your Bond Portfolio, You’re Missing the Point
Worried About a Stock Market Bubble? Here Are 5 Ways to Stay Invested
The 10 Best Dividend Stocks
United States